Bibliography
- Roberts LR. Sorafenib in liver cancer-just the beginning. N Engl J Med 2008;359:420-2
- El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10):745-50
- El-Serag HB, Davila JA, Petersen NJ, The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139(10):817-23
- Lee J-L, Ryu M-H, Chang HM, Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis. J Gastroenterol Hepatol 2008;23(5):811-16
- El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160(21):3227-30
- Bosch FX, Ribes J, Diaz M, Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5-16
- Di Bisceglie AM, Carithers RL Jr, Gores GJ. Hepatocellular carcinoma. Hepatology. 1998;28(4):1161-5
- Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007;11(1):191-207
- Calle EE, Teras LR, Thun MJ. Obesity and mortality. N Engl J Med 2005;353(20):2197-9
- Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17
- Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
- Chang YS, Adnane J, Trail PA, Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-74
- Carlomagno F, Anaganti S, Guida T, BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34
- Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
- Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 2007;356:125-34
- Oh JW, Ahn SM, Kim KS, The role of splenectomy in patients with hepatocellular carcinoma and secondary hypersplenism. Yonsei Medical J 2003;44(6):1053-8
- Poordad F. Review article: thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007;26(1 Suppl):5-11
- Yu MW, Hsu FC, Sheen IS, Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemio 1997;145:1039-47
- Soper NJ, Rikkers LF. Effects of operations for variceal hemorrhage on hypersplenism. Am J Surg 1982;144:700-3
- Ioannou GN, Splan MF, Weiss NS, Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):938-45, 945.e1-4
- Gill ML, Atiq M, Satter S, Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma. J Pak Med Assoc 2005;55(4):135-8
- D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31
- Cheng AL, Kang YK, Chen Z, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
- Akaza H, Tsukamoto T, Murai M, Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37:755-62
- Strumberg D, Jeffrey W Clark, Ahmad Awada, Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12(4):426-37
- Miller AA, Murry DJ, Owzar K, Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301. J Clin Oncol 2007;25(18 Suppl):147s
- Hanna NH, Von Pawel J, Reck M, Carboplatin/paclitaxel with/without sorafenib In chemonaive patients with stage IIIB-IV non-small-cell lung cancer: interim analysis results from a randomized phase III trial (ESCAPE). J Thorac Oncol 2008;3(11):S268
- Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300
- Yau T, Chan P, Ng K, Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients. J Clin Oncol 2008;26(15 Suppl):656s
- Pinter M, Sieghart W, Graziadei I, Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009;14:70-6